trending Market Intelligence /marketintelligence/en/news-insights/trending/n_HE1Obt_RaWaGCjUtxxIA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Mirati Therapeutics prices $300M offering to fund drug development

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Mirati Therapeutics prices $300M offering to fund drug development

Mirati Therapeutics Inc. priced its offering of 3,076,924 common shares at $97.50 each.

The San Diego-based biotechnology company also granted underwriters a 30-day option to buy up to an additional 461,538 common shares.

Gross proceeds are expected to be about $300 million. Net proceeds will be used to develop the company's lung cancer treatment sitravatinib and MRTX849, which is being developed to treat various cancers.

The remaining proceeds will also be used for other general corporate purposes and for working capital.

The offering is expected to close on or about Jan. 14.

Goldman Sachs & Co. LLC, SVB Leerink and Cowen and Co. LLC are acting as joint book-running managers in the offering, while Credit Suisse is acting as lead manager. JonesTrading Institutional Services LLC is serving as a co-manager.